StreetInsider.com News Articles

ABL Diagnostics: Growth Trajectory Confirmed and Strong Upside Potential Identified

Thu, 18 Jun 2026 07:51:00 -0400

Target price: €8.7
Recommendation: Buy

WOIPPY, France--(BUSINESS WIRE)-- Regulatory News:

ABL DIAGNOSTICS (FR001400AHX6 - ABLD-FR), a leading company in the field of molecular diagnostics and genotyping, announces the publication of a new research note (flash note) from Allinvest (Invest Securities) following the announcement of its financial roadmap and growth outlook for 2026.

Invest Securities (AllInvest group) has published a new analyst flash note on ABL Diagnostics, highlighting an expected significant acceleration in growth starting in 2026, supported by solid fundamentals and fully activated growth drivers.

The analyst confirms their positive conviction by reiterating a "Buy" recommendation, while raising the target price

ABL Diagnostics: Growth Trajectory Confirmed and Strong Upside Potential Identified

Thu, 18 Jun 2026 07:51:00 -0400

Target price: €8.7
Recommendation: Buy

WOIPPY, France--(BUSINESS WIRE)-- Regulatory News:

The analyst confirms their positive conviction by reiterating a "Buy" recommendation, while raising the target price

ABL Diagnostics: Growth Trajectory Confirmed and Strong Upside Potential Identified

Thu, 18 Jun 2026 07:51:00 -0400

Target price: €8.7
Recommendation: Buy

WOIPPY, France--(BUSINESS WIRE)-- Regulatory News:

The analyst confirms their positive conviction by reiterating a "Buy" recommendation, while raising the target price

ABL Diagnostics: Growth Trajectory Confirmed and Strong Upside Potential Identified

Thu, 18 Jun 2026 07:51:00 -0400

Target price: €8.7
Recommendation: Buy

WOIPPY, France--(BUSINESS WIRE)-- Regulatory News:

The analyst confirms their positive conviction by reiterating a "Buy" recommendation, while raising the target price

ABL Diagnostics: Growth Trajectory Confirmed and Strong Upside Potential Identified

Thu, 18 Jun 2026 07:51:00 -0400

Target price: €8.7
Recommendation: Buy

WOIPPY, France--(BUSINESS WIRE)-- Regulatory News:

The analyst confirms their positive conviction by reiterating a "Buy" recommendation, while raising the target price

ABL Diagnostics: Growth Trajectory Confirmed and Strong Upside Potential Identified

Thu, 18 Jun 2026 07:51:00 -0400

Target price: €8.7
Recommendation: Buy

WOIPPY, France--(BUSINESS WIRE)-- Regulatory News:

The analyst confirms their positive conviction by reiterating a "Buy" recommendation, while raising the target price

ABL Diagnostics: Growth Trajectory Confirmed and Strong Upside Potential Identified

Thu, 18 Jun 2026 07:51:00 -0400

Target price: €8.7
Recommendation: Buy

WOIPPY, France--(BUSINESS WIRE)-- Regulatory News:

The analyst confirms their positive conviction by reiterating a "Buy" recommendation, while raising the target price

ABL Diagnostics: Growth Trajectory Confirmed and Strong Upside Potential Identified

Thu, 18 Jun 2026 07:51:00 -0400

Target price: €8.7
Recommendation: Buy

WOIPPY, France--(BUSINESS WIRE)-- Regulatory News:

The analyst confirms their positive conviction by reiterating a "Buy" recommendation, while raising the target price

ABL Diagnostics: Growth Trajectory Confirmed and Strong Upside Potential Identified

Thu, 18 Jun 2026 07:51:00 -0400

Target price: €8.7
Recommendation: Buy

WOIPPY, France--(BUSINESS WIRE)-- Regulatory News:

The analyst confirms their positive conviction by reiterating a "Buy" recommendation, while raising the target price

ABL Diagnostics: Growth Trajectory Confirmed and Strong Upside Potential Identified

Thu, 18 Jun 2026 07:51:00 -0400

Target price: €8.7
Recommendation: Buy

WOIPPY, France--(BUSINESS WIRE)-- Regulatory News:

The analyst confirms their positive conviction by reiterating a "Buy" recommendation, while raising the target price

ABL Diagnostics: Growth Trajectory Confirmed and Strong Upside Potential Identified

Thu, 18 Jun 2026 07:51:00 -0400

Target price: €8.7
Recommendation: Buy

WOIPPY, France--(BUSINESS WIRE)-- Regulatory News:

The analyst confirms their positive conviction by reiterating a "Buy" recommendation, while raising the target price

ABL Diagnostics: Growth Trajectory Confirmed and Strong Upside Potential Identified

Thu, 18 Jun 2026 07:51:00 -0400

Target price: €8.7
Recommendation: Buy

WOIPPY, France--(BUSINESS WIRE)-- Regulatory News:

The analyst confirms their positive conviction by reiterating a "Buy" recommendation, while raising the target price

ABL Diagnostics and CDL Pharma Secure a Multi-year International Contract of up to €2.7 Million Through 2031

Fri, 12 Jun 2026 02:00:00 -0400

WOIPPY, France--(BUSINESS WIRE)-- Regulatory News:

ABL Diagnostics (FR001400AHX6 – “ABLD”) announces the signing of a multi-year contract with a European pharmaceutical company in the field of neurodegenerative diseases. The contract relates to services operated by CDL Pharma and distributed by ABL Diagnostics.

This partnership is part of an international clinical program involving 30 centers across 11 countries in North America, Europe, and Asia, reflecting the Group’s ability to support global multicenter studies.

The agreement includes an initial payment exceeding €100,000 upon signature, as well as a total contractual value that could reach approximately €2.7 million through 2031. Revenue will be

ABL Diagnostics and CDL Pharma Secure a Multi-year International Contract of up to €2.7 Million Through 2031

Fri, 12 Jun 2026 02:00:00 -0400

WOIPPY, France--(BUSINESS WIRE)-- Regulatory News:

The agreement includes an initial payment exceeding €100,000 upon signature, as well as a total contractual value that could reach approximately €2.7 million through 2031. Revenue will be

ABL Diagnostics and CDL Pharma Secure a Multi-year International Contract of up to €2.7 Million Through 2031

Fri, 12 Jun 2026 02:00:00 -0400

WOIPPY, France--(BUSINESS WIRE)-- Regulatory News:

The agreement includes an initial payment exceeding €100,000 upon signature, as well as a total contractual value that could reach approximately €2.7 million through 2031. Revenue will be

ABL Diagnostics and CDL Pharma Secure a Multi-year International Contract of up to €2.7 Million Through 2031

Fri, 12 Jun 2026 02:00:00 -0400

WOIPPY, France--(BUSINESS WIRE)-- Regulatory News:

The agreement includes an initial payment exceeding €100,000 upon signature, as well as a total contractual value that could reach approximately €2.7 million through 2031. Revenue will be

ABL Diagnostics and CDL Pharma Secure a Multi-year International Contract of up to €2.7 Million Through 2031

Fri, 12 Jun 2026 02:00:00 -0400

WOIPPY, France--(BUSINESS WIRE)-- Regulatory News:

The agreement includes an initial payment exceeding €100,000 upon signature, as well as a total contractual value that could reach approximately €2.7 million through 2031. Revenue will be

ABL Diagnostics and CDL Pharma Secure a Multi-year International Contract of up to €2.7 Million Through 2031

Fri, 12 Jun 2026 02:00:00 -0400

WOIPPY, France--(BUSINESS WIRE)-- Regulatory News:

The agreement includes an initial payment exceeding €100,000 upon signature, as well as a total contractual value that could reach approximately €2.7 million through 2031. Revenue will be

ABL Diagnostics and CDL Pharma Secure a Multi-year International Contract of up to €2.7 Million Through 2031

Fri, 12 Jun 2026 02:00:00 -0400

WOIPPY, France--(BUSINESS WIRE)-- Regulatory News:

The agreement includes an initial payment exceeding €100,000 upon signature, as well as a total contractual value that could reach approximately €2.7 million through 2031. Revenue will be

ABL Diagnostics and CDL Pharma Secure a Multi-year International Contract of up to €2.7 Million Through 2031

Fri, 12 Jun 2026 02:00:00 -0400

WOIPPY, France--(BUSINESS WIRE)-- Regulatory News:

The agreement includes an initial payment exceeding €100,000 upon signature, as well as a total contractual value that could reach approximately €2.7 million through 2031. Revenue will be

ABL Diagnostics (ABLD) Announces the Submission of a Takeover Bid for Texcell France

Wed, 10 Jun 2026 02:00:00 -0400

WOIPPY, France--(BUSINESS WIRE)-- Regulatory News:

ABL Diagnostics (Paris:ABLD) (Euronext Paris – Compartment B – ISIN: FR001400AHX6), a company specialized in molecular diagnostic solutions, healthcare software, and clinical sample management, announces that on Tuesday, June 9, 2026, it submitted a bid to acquire the business and assets of TEXCELL, a company specialized in viral safety testing, immunology, and R&D services for biopharmaceutical products, currently subject to judicial reorganization proceedings before the Commercial Court of Évry.

This initiative is part of ABL Diagnostics’ development strategy aimed at assessing external growth opportunities complementary to its current portfolio.

This proposed acquisition, based on Article

ABL Diagnostics (ABLD) Announces the Submission of a Takeover Bid for Texcell France

Wed, 10 Jun 2026 02:00:00 -0400

WOIPPY, France--(BUSINESS WIRE)-- Regulatory News:

This initiative is part of ABL Diagnostics’ development strategy aimed at assessing external growth opportunities complementary to its current portfolio.

This proposed acquisition, based on Article

ABL Diagnostics (ABLD) Announces the Submission of a Takeover Bid for Texcell France

Wed, 10 Jun 2026 02:00:00 -0400

WOIPPY, France--(BUSINESS WIRE)-- Regulatory News:

This initiative is part of ABL Diagnostics’ development strategy aimed at assessing external growth opportunities complementary to its current portfolio.

This proposed acquisition, based on Article

ABL Diagnostics (ABLD) Announces the Submission of a Takeover Bid for Texcell France

Wed, 10 Jun 2026 02:00:00 -0400

WOIPPY, France--(BUSINESS WIRE)-- Regulatory News:

This initiative is part of ABL Diagnostics’ development strategy aimed at assessing external growth opportunities complementary to its current portfolio.

This proposed acquisition, based on Article

ABL Diagnostics (ABLD) Announces the Submission of a Takeover Bid for Texcell France

Wed, 10 Jun 2026 02:00:00 -0400

WOIPPY, France--(BUSINESS WIRE)-- Regulatory News:

This initiative is part of ABL Diagnostics’ development strategy aimed at assessing external growth opportunities complementary to its current portfolio.

This proposed acquisition, based on Article